ACM
OTLK icon

Alamar Capital Management’s Outlook Therapeutics OTLK Stock Holding History

Alamar Capital Management’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,000
Closed -$34.8K – 72
2023
Q2 		$34.8K Hold
1,000
– – 0.03% 78
2023
Q1 		$21.8K Hold
1,000
– – 0.02% 69
2022
Q4 		$21.6K Sell
1,000
-175
-15% -$3.81K 0.02% 69
2022
Q3 		$29K Buy
1,175
+175
+18% +$4.07K 0.03% 69
2022
Q2 		$20K Hold
1,000
– – 0.02% 61
2022
Q1 		$36K Hold
1,000
– – 0.03% 63
2021
Q4 		$27K Buy
+1,000
New +$35.7K 0.02% 64

Other funds holding OTLK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $24.3B AUM 29.21% 1-Year Est. Return
LNC
Lincoln National Corp Radnor, Pennsylvania $3.45B AUM 12.55% 1-Year Est. Return

Alamar Capital Management's OTLK Position: Q3 2023 in Review

Alamar Capital Management sold out of Outlook Therapeutics (OTLK) in Q3 2023, closing a stake of 1,000 shares — an estimated $34.8K sold.

Alamar Capital Management first reported a position in OTLK in Q4 2021 and held it in 7 quarters. The position peaked at $36K in Q1 2022. 81 funds tracked by Wall St. Rank hold OTLK as of Q3 2023.

  • Alamar Capital Management reported no remaining Outlook Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Alamar Capital Management sold 1,000 Outlook Therapeutics shares in Q3 2023, an estimated $34.8K.
  • Alamar Capital Management first reported a position in Outlook Therapeutics in Q4 2021 and held it in 7 quarters.
  • Alamar Capital Management's Outlook Therapeutics position peaked at $36K in Q1 2022.
  • 81 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q3 2023.

Based on Alamar Capital Management's 13F filing for Q3 2023, filed 29 Nov 2023.